Infectious features of atherosclerosis;Aspects infectieux de l'athérosclérose

Medecine/Sciences

Volumn 20, Issue 2, 2004, Pages 169-174

  Wyplosz, Benjamin ^a,b   Capron, Loïc ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACTERIUM; CORONARY ARTERY DISEASE; HUMAN; IMMUNIZATION; INFECTION; INFLAMMATION; REVIEW; VIRUS;

BACTERIA (MICROORGANISMS);

EID: 1042268201     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2004202169     Document Type: Review

References (32)

1. Capron L. Étiologie de l'athérosclérose. Rev Prat 1999; 49: 2100-3.
2. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998; 148: 937-48.
3. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-40.
4. Saikku P, Leinonen M, Mattila. K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1999; 2: 983-5.
5. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment strategies. Clin Microb Rev 2002; 15: 1-20.
6. Mendall M, Goggin P, Levy J, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-9.
7. Gupta S, Leatham EW, Carrington D, Mendall MA, Koski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
8. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-7.
9. Epstein SE, Zhu JH, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000; 20: 1417-20.
10. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. JAMA 2000; 284: 1406-10.
11. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105: 15-21.
12. Danesh J, Nhincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. Br Med J 2000; 321: 208-12.
13. Smieja M, Chong S, Natarajan M, et al. Circulating nucleic acids of Chlamydia pneumoniae and cytomegalovirus in patients undergoing coronary angiography. J Clin Microbiol 2001; 39: 596-600.
14. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
15. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke 2001; 32: 385-90.
16. Farsak B, Yildirir A, Akyon Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000; 38: 4408-11.
17. Capron L. Chlamydia in coronary plaques: Hidden culprit or harmless hobo? Nat Med 1996; 2: 856-7.
18. Fabricant CG. Atherosclerosis: the consequence of infection with a herpesvirus. Adv Vet Sci Comp Med 1985; 30: 39-66.
19. Capron L. How to design vaccination trials to prevent atherosclerosis. Am Heart J 1999; 138: S558-9.
20. Morré SA, Stooker W, Lagrand WK, van den Brule AJC, Niessen HWM. Microorganisms in the aetiology of atherosclerosis. J Clin Pathol 2000; 53: 647-54.
21. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 2000; 181: S473-8.
22. Stone AFM, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106: 1219-23.
23. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999; 20: 89-92.
24. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndromes. Circulation 2002; 105: 1555-60.
25. st Annual Meeting, March 17-20, 2002. Atlanta, Georgia: American College of Cardiology, 2002 (abstract 405-3).
26. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation 2000; 102: 1755-60.
27. Neumann FJ, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001; 357: 2085-9.
28. st Annual Meeting, March 17-20, 2002. Atlanta, Georgia: American College of Cardiology, 2002 (abstract 405-4).
29. Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered form atherosclerotic coronary arteries. Antimicrob Agents Chemother 1998; 42: 2762-4.
30. Schneider C, Diedrich H, Riedel KD, et al. In vivo uptake of azithromycin in human coronary plaque. Am J Cardiol 2000; 86: 789-91.
31. Beatty W, Morrison R, Byrne G. Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58: 686-99.
32. Gieffers J, Füllgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-6.